Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications
Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy.
Journal: Neurodegenerative disease management
Published: October 07, 2025
Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis.
Journal: Journal of comparative effectiveness research
Published: September 12, 2025
Analysis of diroximel fumarate data for patients with relapsing forms of multiple sclerosis using related adverse events from the FDA adverse reporting system.
Journal: Expert opinion on drug safety
Published: April 02, 2025
Transition from anti-CD20 therapies to fumarates as a treatment strategy: A multicenter, retrospective observational experience.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: April 01, 2025
Targeted activation of Nrf2 at sites of oxidative stress reverses doxorubicin-induced cognitive impairments in mice.
Journal: Brain, behavior, and immunity
Published: March 30, 2025
Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005).
Journal: Neurology
Published: February 20, 2025
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA.
Journal: Neurology and therapy
Published: February 12, 2025
Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis.
Journal: Neurology and therapy
Published: February 12, 2025
Severe gastrointestinal adverse reactions including perforation, ulceration, hemorrhage, and obstruction: A fumaric acid ester class new safety risk.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 11, 2025
Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons.
Journal: Diabetes
Published: January 30, 2025
Safety and effectiveness of diroximel fumarate in relapsing forms of multiple sclerosis: a systematic review and meta-analysis.
Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: December 29, 2024
Last Updated: 10/31/2025